Vol. 18/No. 07 | OncologyLive

Liquid Biopsy Testing Detects Recurrence in High-Risk NSCLC

April 13, 2017

The results of a recent prospective study demonstrate that circulating tumor cells can reveal disease recurrence an average of 6 months prior to conventional imaging in patients with locally advanced non–small cell lung cancer, findings that may help support the use of liquid biopsies to monitor high-risk patients in conjunction with screening.

Beyond Myeloma: New Roles for IMiDs

April 10, 2017

The past several decades have witnessed a dramatic improvement in the treatment of patients with multiple myeloma, the second most common type of hematologic malignancy. A better understanding of the biology of this disease and the introduction of a wealth of novel drug classes has more than doubled median survival times.

Bloomfield Challenged Status Quo for Patients With Leukemia and Women in Science

April 09, 2017

Clara D. Bloomfield, MD, a groundbreaking researcher in adult leukemia and lymphoma who helped define new roles for women in science, was honored in the Myeloid Neoplasms category with a 2015 Giants of Cancer Care® award, a program that OncLive® developed to recognize leaders in the field.

RCC Advances Shake Up Drug Choices

April 07, 2017

Axitinib was a promising newcomer in the renal cell carcinoma field when it was introduced as a second-line therapy 5 years ago. Now it is being displaced by newer therapies, a development that may serve as a harbinger for the evolution of treatment patterns in other tumor types with a bounty of novel agents.

Novel HER2 Inhibitor May Help Treat Brain Tumors in Breast Cancer Patients

April 07, 2017

Investigators are seeking to determine whether adding tucatinib (ONT-380), a novel small-molecule HER2 inhibitor, to standard therapies will improve outcomes for patients with progressive metastatic HER2-positive breast cancer, including those with brain tumors.

Simplified Summaries of Trial Data Needed for Patients and Their Oncologists

April 07, 2017

Despite the importance of clinical trial data, there are problems with the way these data are presented. There is a need to simplify what is being discussed so that it can be more easily understood or summarized by patients and their advisers in their decision-making process.

Epigenetic Studies May Unlock Clues to Gene Mutations

April 07, 2017

Researchers at Roswell Park Cancer Institute are formalizing their epigenetics program across dozens of disease research groups, with the goal of understanding what changes in the epigenome lead to cancer and identifying targeted, personalized ways to address these changes.

Caught up in Change

April 05, 2017

The relentless pace of change in cancer research and care is hardly news to practicing oncologists. It is worthwhile, however, to pause at times and ponder the implications of the speed and complexity of those developments.